• Health Canada has accepted Vertex Pharmaceuticals’ (NasdaqGS:VRTX) new pain therapy suzetrigine for regulatory review.
• The drug is a non opioid, non NSAID option for acute pain that could represent the first new class of such medicines in Canada in over two decades.
• The review marks a regulatory milestone for Vertex beyond its core genetic disease portfolio.

For you as an investor, this development moves Vertex beyond its established focus on genetic diseases into a different treatment area. Acute pain treatment is an area long dominated by opioids and NSAIDs, so a potential new class of therapy highlights how the company is using its research capabilities outside cystic fibrosis and other inherited conditions.

Health Canada’s review…